Harrow (NASDAQ:HROW) Price Target Raised to $65.00 at Craig Hallum

Harrow (NASDAQ:HROW) had its price target raised by Craig Hallum from $45.00 to $65.00 in a research note released on Friday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, B. Riley reiterated a buy rating and set a $50.00 price objective on shares of Harrow in a research report on Thursday, August 29th.

Harrow Stock Up 0.5 %

HROW opened at $50.64 on Friday. The stock’s 50 day moving average price is $39.46 and its 200 day moving average price is $24.79. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.60 and a quick ratio of 2.43. The stock has a market cap of $1.79 billion, a P/E ratio of -55.65 and a beta of 0.75. Harrow has a 12 month low of $7.60 and a 12 month high of $51.81.

Harrow (NASDAQ:HROW) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.12. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. The firm had revenue of $48.94 million during the quarter, compared to the consensus estimate of $42.78 million. As a group, research analysts predict that Harrow will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Harrow by 1.2% during the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock worth $24,208,000 after buying an additional 21,253 shares during the last quarter. Woodmont Investment Counsel LLC increased its position in Harrow by 73.3% during the first quarter. Woodmont Investment Counsel LLC now owns 211,579 shares of the company’s stock worth $2,799,000 after acquiring an additional 89,510 shares during the period. Private Capital Management LLC raised its stake in Harrow by 7.8% during the 1st quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock valued at $39,854,000 after purchasing an additional 217,896 shares during the last quarter. Apis Capital Advisors LLC bought a new stake in Harrow in the 2nd quarter valued at $1,660,000. Finally, Bank of New York Mellon Corp grew its position in Harrow by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 88,210 shares of the company’s stock worth $1,843,000 after purchasing an additional 12,580 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.